Suppression of interleukin-11-mediated bone resorption by cyclooxygenases inhibitors

被引:0
|
作者
Morinaga, Y
Fujita, N
Ohishi, K
Zhang, YK
Tsuruo, T
机构
[1] Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 113, Japan
[2] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
关键词
D O I
10.1002/(SICI)1097-4652(199806)175:3<247::AID-JCP2>3.3.CO;2-E
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We previously found that human melanoma (A375M) and human breast cancer (MDA-MB-231) cells formed osteolytic bone metastasis in vivo. These cancer cells produced interleukin-11 (IL-11) by themselves and stimulated its production from osteoblasts. Interleukin-ll could increase the number of osteoclasts and raise the calcium concentration in the medium of neonatal murine calvaria organ culture, indicating bone resorption in vitro. Therefore, IL-ll could play an important role in the promotion of osteolysis at the site of bone metastasis. in the present study, we used the calvaria culture system to try to clarify the mechanisms of IL-ll-mediated bone resorption. The murine calvaria expressed both the specificity-determining oc subunit and the signal-transducing beta subunit (gp130) of the IL-ll receptor. When IL-ll was added to the calvaria culture, the concentrations of prostaglandin E-2 (PGE(2)) was elevated. Pretreatment of calvaria with cyclooxygenases inhibitors (e.g., indomethacin, NS-398, and dexamethasone) suppressed the production of PGE, and the bone resorption induced by IL-11. Addition of exogenous PGE, overcame the inhibitory effect of cyclooxygenases inhibitors and promoted bone resorption. These results indicate that IL-l 1 promotes bone resorption through a PGE, synthesis-dependent mechanism and that cyclooxygenases inhibitors could be interesting drugs to suppress IL-11-mediated osteolytic bone metastasis of cancer cells. (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:247 / 254
页数:8
相关论文
共 50 条
  • [31] MECHANISM OF OSTEOCLAST MEDIATED BONE-RESORPTION
    VAANANEN, HK
    HENTUNEN, T
    LAKKAKORPI, P
    PARVINEN, EK
    SUNDQVIST, K
    TUUKKANEN, J
    ANNALES CHIRURGIAE ET GYNAECOLOGIAE, 1988, 77 (5-6) : 193 - 196
  • [32] Selective cathepsin K inhibitors prevent osteoclast-mediated bone resorption in vitro and in vivo.
    Drake, FH
    James, IE
    Bradbeer, J
    Tomaszek, T
    Bossard, M
    Levy, M
    Janson, C
    Smith, W
    Zhao, B
    McQueney, M
    Desjarlais, R
    LeeRykaczewski, E
    Zembryki, D
    Yamashita, D
    Marquis, R
    Halbert, S
    Thompson, S
    Veber, D
    Gowen, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : T369 - T369
  • [33] Inhibitors of bone resorption in breast cancer metastatic to bone: A critical appraisal
    Body, J. J.
    CANCER TREATMENT REVIEWS, 2006, 32 : S26 - S26
  • [34] Inhibitors of bone resorption for the treatment of bone metastases: Current status and perspectives
    Body, J. -J.
    ONCOLOGIE, 2015, 17 (03) : 117 - 126
  • [35] Hypoxia-Induced Fibroblast Growth Factor 11 Stimulates Osteoclast-Mediated Resorption of Bone
    Knowles, Helen J.
    CALCIFIED TISSUE INTERNATIONAL, 2017, 100 (04) : 382 - 391
  • [36] How do bone resorption inhibitors increase bone mineral density?
    Boivin, G
    Meunier, PJ
    REVUE DU RHUMATISME, 1999, 66 (11): : 534 - 537
  • [37] Hypoxia-Induced Fibroblast Growth Factor 11 Stimulates Osteoclast-Mediated Resorption of Bone
    Helen J. Knowles
    Calcified Tissue International, 2017, 100 : 382 - 391
  • [38] Nitrosylated NSAIDs are potent inhibitors of bone resorption in vitro
    Mohamed, AII
    Armour, KJ
    del Soldato, P
    Ralston, SH
    Van't Hof, RJ
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (06) : 1175 - 1175
  • [39] The experimental study on the effect calcitonin gene-related peptide on bone resorption mediated by interleukin-1
    Lian Kai
    Du Jingyuan
    Rao Zhenyu
    Luo Huaican
    Current Medical Science, 2001, 21 (4) : 304 - 307
  • [40] αvβ3 integrin antagonists as inhibitors of bone resorption
    Hartman, GD
    Duggan, ME
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (06) : 1281 - 1291